Use: Labeled indications
- INDICATIONS AND USAGE Bisoprolol fumarate is indicated in the management of hypertension.
Full indications and usage US FDA label
INDICATIONS AND USAGE Bisoprolol fumarate is indicated in the management of hypertension. It may be used alone or in combination with other antihypertensive agents.
Contraindications
CONTRAINDICATIONS Bisoprolol fumarate is contraindicated in patients with cardiogenic shock, overt cardiac failure, second or third degree AV block, and marked sinus bradycardia.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION The dose of bisoprolol fumarate must be individualized to the needs of the patient. The usual starting dose is 5 mg once daily. In some patients, 2.5 mg may be an appropriate starting dose (see Bronchospastic Disease in WARNINGS). If the antihypertensive effect of 5 mg is inadequate, the dose may be increased to 10 mg and then, if necessary, to 20 mg once daily.
Patients with Renal or Hepatic Impairment In patients with hepatic impairment (hepatitis or cirrhosis) or renal dysfunction (creatinine clearance less than 40 mL/min), the initial daily dose should be 2.5 mg and caution should be used in dose-titration. Since limited data suggest that bisoprolol fumarate is not dialyzable, drug replacement is not necessary in patients undergoing dialysis.
Geriatric Patients It is not necessary to adjust the dose in the elderly, unless there is also significant renal or hepatic dysfunction (see above and Geriatric Use in PRECAUTIONS). Pediatric Patients There is no pediatric experience with bisoprolol fumarate.
Dosing: Altered kidney function
Patients with Renal or Hepatic Impairment In patients with hepatic impairment (hepatitis or cirrhosis) or renal dysfunction (creatinine clearance less than 40 mL/min), the initial daily dose should be 2.5 mg and caution should be used in dose-titration.
Since limited data suggest that bisoprolol fumarate is not dialyzable, drug replacement is not necessary in patients undergoing dialysis.
Geriatric Patients It is not necessary to adjust the dose in the elderly, unless there is also significant renal or hepatic dysfunction (see above and Geriatric Use in PRECAUTIONS).
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
Pediatric Use Safety and effectiveness in pediatric patients have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
Geriatric Use Bisoprolol fumarate has been used in elderly patients with hypertension. Response rates and mean decreases in systolic and diastolic blood pressure were similar to the decreases in younger patients in the U.S. clinical studies. Although no dose response study was conducted in elderly patients, there was a tendency for older patients to be maintained on higher doses of bisoprolol fumarate.
Observed reductions in heart rate were slightly greater in the elderly than in the young and tended to increase with increasing dose. In general, no disparity in adverse experience reports or dropouts for safety reasons was observed between older and younger patients. Dose adjustment based on age is not necessary.
Dosage forms
Philippines
- Film-coated tablet: 2.5 mg, 5 mg, 10 mg
- Tablet: 2.5 mg, 5 mg
Registered products in the Philippines
60 products registered with the Food and Drug Administration (FDA) Philippines list Bisoprolol as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products60
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
B1blocBisoprolol fumarate | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | HealthPrescription, Inc.Importer: Ambica International Corporation | DRP-2287-03 | Jun 28, 2030 | |
Biscore 2.5Bisoprolol fumarate | 2.5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Unison Laboratories Co., Ltd.Thailand | JustRight Healthcare Inc. | DRP-14428 | Mar 12, 2031 | |
Biscore 5Bisoprolol fumarate | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Unison Laboratories Co., Ltd.Thailand | JustRight Healthcare Inc. | DRP-14429 | Mar 12, 2031 | |
Bisobloc 10Bisoprolol Fumarate | 10mg Film-coated TabletAlu/PVC Blister Pack x 20's (Box of 20's, 60's and 100's) | RxVAT-exempt | Phil. United Pharma Corp.Philippines | Trader: ATC Healthcare International Corp. | DRP-14319 | Aug 17, 2028 | |
Bisobloc 5Bisoprolol Fumarate | 5mg Film-Coated TabletAlu/PVC Blister Pack x 20's (Box of 20's, 60's and 100's) | RxVAT-exempt | Phil. United Pharma Corp.Philippines | ATC Healthcare International Corp. | DRP-13330 | Jan 27, 2028 | |
BisocardBisoprolol fumarate | 5 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Corona Remedies Pvt. Ltd.India | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-17927-01 | Apr 13, 2031 | |
BisocorBisoprolol Fumarate | 2.5 mg TabletAlu-PVDC Blister pack x 10's (Box of 100's) | RxVAT-exempt | Y.S.P. Industries (M) Sdn. Bhd.Malaysia | Importer: Yung Shin (Philippines), Inc., | DR-XY48177 | Jul 11, 2027 | |
BisocorBisoprolol Fumarate | 5 mg TabletAlu/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Y.S.P. Industries (M) Sdn. Bhd.Malaysia | Yung Shin (Philippines), Inc., | DR-XY48187 | Jul 13, 2027 | |
Bisodac 10Bisoprolol fumarate | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 14's (Box of 2 blister packs x 14 tablets) | RxVAT-exempt | Aurobindo Pharma LimitedIndia | AAA Pharma, Inc. | DR-XY48353 | Sep 16, 2027 | |
Bisodac 2.5Bisoprolol Fumarate | 2.5mg Film-Coated TabletAlu/Alu Blister Pack x 14's (Box of 2 blister packs x 14 tablets) | RxVAT-exempt | Aurobindo Pharma LimitedIndia | AAA Pharma, Inc. | DR-XY48354 | Sep 15, 2027 | |
Bisodac 5Bisoprolol Fumarate | 5mg Film-Coated TabletAlu/Alu Blister Pack x 14's (Box of 2 blister packs x 14 tablets) | RxVAT-exempt | Aurobindo Pharma LimitedIndia | AAA Pharma, Inc. | DR-XY48352 | Sep 15, 2027 | |
BisolabBisoprolol fumarate | 5 mg Film-coated tabletAlu-Alu blister pack x 10’s (Box of 30’s) | RxVAT-exempt | Medisure Laboratories Pakistan (Pvt.) Ltd.Pakistan | EuroAsia Pharmaceuticals Inc. | DRP-12553 | Sep 1, 2032 | |
BisophilBisoprolol fumarate | 10 mg Film Coated TabletAlu/Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-13805 | Apr 25, 2028 | |
BisophilBisoprolol fumarate | 2.5 mg Film Coated TabletAlu/Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-13804 | Apr 25, 2028 | |
BisophilBisoprolol fumarate | 5 mg Film Coated TabletAlu/Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-13803 | Apr 25, 2028 | |
BisoprolifeBisoprolol Fumarate | 2.5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Medico Remedies LimitedIndia | Vitalife Pharma & Medical Supply Inc.Importer: Medethix, Inc. | DRP-14207-01 | Jul 21, 2028 | |
Bisopromed-2.5Bisoprolol fumarate | 2.5 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Corona Remedies Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-17928 | Apr 13, 2031 | |
Bisopromed-5Bisoprolol fumarate | 5 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Corona Remedies Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-17927 | Apr 13, 2031 | |
BisostenBisoprolol fumarate | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Mc Graw Pharma Inc.Importer: Ambica International Corporation | DRP-2287 | Jun 28, 2030 | |
BisotechBisoprolol fumarate | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | One Technodrug Life Sciences Inc.Importer: Ambica International Corporation | DRP-2287-05 | Jun 28, 2030 | |
Bisotrol 10Bisoprolol Fumarate | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Ipca Laboratories Ltd.India | Blue Global (FZE) | DRP-12475 | Aug 16, 2027 | |
Bisotrol 5Bisoprolol Fumarate | 5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Ipca Laboratories Ltd.India | Blue Global (FZE) | DRP-12474 | Aug 16, 2027 | |
BisovellBisoprolol fumarate | 5 mg Film Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | PT. Novell Pharmaceutical LaboratoriesIndonesia | Prosweal Healthcare Inc. | DR-XY49078 | May 13, 2029 | |
BistaproBisoprolol fumarate | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lek S.A.Poland | STADA Philippines Inc.Importer: Sandoz Philippines Corporation | DRP-2514-03 | Apr 17, 2027 | |
ConcoreBisoprolol Fumarate | 10 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 30’s) | RxVAT-exempt | Merck Healthcare KGaAGermany | Importer: Merck, Inc. | DRP-7724 | Mar 18, 2029 | |
ConcoreBisoprolol Fumarate | 2.5 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Merck Healthcare KGaAGermany | Importer: Merck, Inc. | DRP-7722 | Nov 9, 2037 | |
ConcoreBisoprolol Fumarate | 5 mg Film-Coated TabletPVC/HSL Alu Blister Pack x 10's (Box off 100's) | RxVAT-exempt | PT Merck TBKIndonesia | Merck, Inc. | DRP-6628 | Dec 26, 2026 | |
DocbetaBisoprolol fumarate | 10mg Film Coated TabletAlu/PVC Blister Pack x 20's (Box of 20's, 60's and 100's) | RxVAT-exempt | Phil. United Pharma Corp.Philippines | Trader: Docteur's Choice Corporation | DRP-14320 | Aug 17, 2028 | |
DocbetaBisoprolol Fumarate | 5 mg Film-Coated TabletAlu/PVC Blister Pack x 20's (Box of 20's, 60's and 100's) | RxVAT-exempt | Phil. United Pharma Corp.Philippines | Trader: Docteur's Choice Corporation | DRP-13331 | Jan 27, 2028 | |
EpiblocBisoprolol fumarate | 5 mg Film-Coated TabletAlu/clear PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | ACME Formulation Pvt. Ltd.India | SRS Life Sciences, Inc. | DR-XY48912 | Oct 27, 2028 | |
GolbetaBisoprolol fumarate | 10mg Film-coated TabletAlu/PVC Blister Pack x 20's (Box of 20's, 60's and 100's) | RxVAT-exempt | Phil. United Pharma Corp.Philippines | Trader: Golden Dale Pharma Corp. | DRP-14321 | Aug 17, 2028 | |
GolbetaBisoprolol Fumarate | 5 mg Film-Coated TabletAlu/PVC Blister Pack x 20's (Box of 20's, 60's and 100's) | RxVAT-exempt | Phil. United Pharma Corp.Philippines | Trader: Golden Dale Pharma Corp. | DRP-13332 | Jan 27, 2028 | |
Lobiso 10Bisoprolol fumarate | 10 mg Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | LEK S.A.Poland | Emcure Pharma Philippines Inc.Importer: Sandoz Philippines Corporation | DRP-2513-02 | Apr 17, 2027 | |
NoneBisoprolol fumarate | 10 mg Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 100’s) | RxVAT-exempt | LEK S.A.Poland | Importer: Sandoz Philippines Corporation | DRP-2513 | Apr 17, 2037 | |
NoneBisoprolol fumarate | 10 mg Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lek S.A.Poland | Ritemed Phils., Inc.Importer: Sandoz Philippines Corporation | DRP-2513-01 | Apr 17, 2027 | |
NoneBisoprolol Fumarate | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Merck Healthcare KGaAGermany | Philusa CorporationImporter: Merck, Inc. | DRP-7724-01 | Mar 18, 2029 | |
NoneBisoprolol Fumarate | 2.5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Dr. Zen's Research, Inc. | DRP-18025 | Apr 23, 2031 | |
NoneBisoprolol Fumarate | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Dr. Zen's Research, Inc. | DRP-18024 | Apr 23, 2031 | |
NoneBisoprolol fumarate | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Actimed, Inc.Importer: Ambica International Corporation | DRP-2287-01 | Jun 28, 2030 | |
NoneBisoprolol fumarate | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-2287-02 | Jun 28, 2030 | |
NoneBisoprolol fumarate | 5 mg Film-coated TabletAlu/Alu Blister Pack x 10's Box of 100's | RxVAT-exempt | Lek S.A.Poland | Ritemed Phils., Inc.Importer: Sandoz Philippines CorporationTrader: IA Pharma GmbH | DRP-2514-01 | Apr 17, 2027 | |
NoneBisoprolol Fumarate | 5 mg Film-Coated TabletPVC/HSL Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | PT. Merck TBKIndonesia | Philusa CorporationImporter: Merck, Inc. | DRP-6628-01 | Dec 29, 2026 | |
Sopalol 10Bisoprolol Fumarate | 10mg Film Coated TabletAlu-Alu blister pack x 14's (Box of 28's) | RxVAT-exempt | INTAS PHARMACEUTICALS LIMITEDIndia | Accord Healthcare Limited - Philippine Branch Office | DRP-8148 | Apr 3, 2029 | |
SoprozenBisoprolol fumarate | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Kodapharm Med Corp.Importer: Ambica International Corporation | DRP-2287-04 | Jun 28, 2030 | |
UnbrandedBisoprolol Fumarate | 2.5 mg Film-Coated TabletAlu-Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Merck Healthcare KGaAGermany | Philusa CorporationImporter: Merck, Inc. | DRP-7722-01 | Oct 20, 2031 | |
UnbrandedBisoprolol fumarate | 5 mg Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 100’s) | RxVAT-exempt | LEK S.A.Poland | Importer: Sandoz Philippines Corporation | DRP-2514 | Apr 17, 2037 | |
XinblocBisoprolol Fumarate | 2.5 mg TabletAlu/PVC Blister Pack in Aluminum Foil Bag x 14's (Box of 28's) | RxVAT-exempt | Zhejiang Jingxin Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-17777 | Mar 11, 2031 | |
XinblocBisoprolol Fumarate | 5 mg TabletAlu/PVC Blister Pack in Aluminum Foil Bag x 14's (Box of 28's) | RxVAT-exempt | Zhejiang Jingxin Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-17778 | Mar 11, 2031 | |
ZolblocBisoprolol Fumarate | 5 mg Film-Coated TabletAlu-Alu blister pack 10's (Box of 30's) | RxVAT-exempt | WESTCOAST PHARMACEUTICAL WORKS LTD.India | Aglobal Care, Inc. | DRP-19062 | Oct 22, 2031 | |
(no brand name)Bisoprolol Fumarate | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 3 blister packs x 30 tablets) | RxVAT-exempt | United International Pharma Co. Ltd.Vietnam | Ritemed Phils., Inc.Trader: Concord Pharmaceuticals Limited | DRP-12694 | Sep 23, 2027 | |
(no brand name)Bisoprolol Fumarate | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Dr. Zen's Research, Inc. | DRP-18023 | Apr 23, 2031 | |
(no brand name)Bisoprolol fumarate | 10 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | — | DRP-18413 | Jul 2, 2031 | |
(no brand name)Bisoprolol fumarate | 10mg Film-coated TabletAlu/PVC Blister Pack x 20's (Box of 20's, 60's and 100's) | RxVAT-exempt | Phil. United Pharma Corp.Philippines | — | DRP-14318 | Aug 17, 2028 | |
(no brand name)Bisoprolol Fumarate | 2.5 mg Film Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Medico Remedies LimitedIndia | MedEthix, Inc. | DRP-14207 | Jul 21, 2028 | |
(no brand name)Bisoprolol (as Fumarate) | 2.5 mg Film-Coated TabletAlu-Alu Blister pack x 10's (Box of 30's) | RxVAT-exempt | United International Pharma Co.Vietnam | Importer: Ritemed Phils., Inc. | DRP-12087 | Jun 9, 2027 | |
(no brand name)Bisoprolol fumarate | 2.5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories Inc.Philippines | — | DRP-18258 | Jun 4, 2031 | |
(no brand name)Bisoprolol Fumarate | 5 mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Medico Remedies LimitedIndia | MedEthix, Inc. | DRP-16449 | Mar 18, 2027 | |
(no brand name)Bisoprolol fumarate | 5 mg Film-Coated TabletAlu-Alu Blister pack x 10's (Box of 30's) | RxVAT-exempt | United International Pharma Co., Ltd.Vietnam | RiteMED Phils., Inc. | DR-XY48098 | Jun 9, 2027 | |
(no brand name)Bisoprolol fumarate | 5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories Inc.Philippines | — | DRP-18256 | Jun 4, 2031 | |
(no brand name)Bisoprolol Fumarate | 5mg Film-Coated TabletAlu/PVC Blister Pack x 20's (Box of 20's, 60's and 100's) | RxVAT-exempt | Phil. United Pharma Corp.Philippines | — | DRP-13329 | Jan 27, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS Cardiac Failure Sympathetic stimulation is a vital component supporting circulatory function in the setting of congestive heart failure, and beta-blockade may result in further depression of myocardial contractility and precipitate more severe failure. In general, beta-blocking agents should be avoided in patients with overt congestive failure.
However, in some patients with compensated cardiac failure it may be necessary to utilize them. In such a situation, they must be used cautiously. In Patients Without a History of Cardiac Failure Continued depression of the myocardium with beta-blockers can, in some patients, precipitate cardiac failure. At the first signs or symptoms of heart failure, discontinuation of bisoprolol fumarate should be considered.
In some cases, beta-blocker therapy can be continued while heart failure is treated with other drugs. Abrupt Cessation of Therapy Exacerbation of angina pectoris, and, in some instances, myocardial infarction or ventricular arrhythmia, has been observed in patients with coronary artery disease following abrupt cessation of therapy with beta-blockers.
Such patients should, therefore, be cautioned against interruption or discontinuation of therapy without the physician’s advice. Even in patients without overt coronary artery disease, it may be advisable to taper therapy with bisoprolol fumarate over approximately one week with the patient under careful observation. If withdrawal symptoms occur, bisoprolol fumarate therapy should be reinstituted, at least temporarily.
Peripheral Vascular Disease Beta-blockers can precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease. Caution should be exercised in such individuals. Bronchospastic Disease PATIENTS WITH BRONCHOSPASTIC DISEASE SHOULD, IN GENERAL, NOT RECEIVE BETA-BLOCKERS. Because of its relative beta1-selectivity, however, bisoprolol fumarate may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment.
Since beta1-selectivity is not absolute, the lowest possible dose of bisoprolol fumarate should be used, with therapy starting at 2.5 mg. A beta2 agonist (bronchodilator) should be made available. Major Surgery Chronically administered beta-blocking therapy should not be routinely withdrawn prior to major surgery; however, the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risk of general anesthesia and surgical procedures.
Diabetes and Hypoglycemia Beta-blockers may mask some of the manifestations of hypoglycemia, particularly tachycardia. Nonselective beta-blockers may potentiate insulin-induced hypoglycemia and delay recovery of serum glucose levels. Because of its beta1-selectivity, this is less likely with bisoprolol fumarate. However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution.
Thyrotoxicosis Beta-adrenergic blockade may mask clinical signs of hyperthyroidism, such as tachycardia. Abrupt withdrawal of beta-blockade may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate thyroid storm.
Drug interactions
Drug interactions (US label) US FDA label
Drug Interactions Bisoprolol fumarate should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of bisoprolol fumarate may produce excessive reduction of sympathetic activity.
In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that bisoprolol fumarate be discontinued for several days before the withdrawal of clonidine. Bisoprolol fumarate should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.
Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate, resulting in a shortened elimination half-life of bisoprolol fumarate. However, initial dose modification is generally not necessary.
Pharmacokinetic studies document no clinically relevant interactions with other agents given concomitantly, including thiazide diuretics and cimetidine. There was no effect of bisoprolol fumarate on prothrombin time in patients on stable doses of warfarin. Risk of Anaphylactic Reaction: While taking beta-blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic.
Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reactions.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS Safety data are available in more than 30,000 patients or volunteers. Frequency estimates and rates of withdrawal of therapy for adverse events were derived from two U.S. placebo-controlled studies. In Study A, doses of 5, 10, and 20 mg bisoprolol fumarate were administered for 4 weeks. In Study B, doses of 2.5, 10, and 40 mg of bisoprolol fumarate were administered for 12 weeks.
A total of 273 patients were treated with 5 to 20 mg of bisoprolol fumarate; 132 received placebo. Withdrawal of therapy for adverse events was 3.3% for patients receiving bisoprolol fumarate and 6.8% for patients on placebo. Withdrawals were less than 1% for either bradycardia or fatigue/lack of energy. The following table presents adverse experiences, whether or not considered drug related, reported in at least 1% of patients in these studies, for all patients studied in placebo-controlled clinical trials (2.5 to 40 mg), as well as for a subgroup that was treated with doses within the recommended dosage range (5 to 20 mg).
Of the adverse events listed in the table, bradycardia, diarrhea, asthenia, fatigue, and sinusitis appear to be dose related. Body System/Adverse Experience All Adverse Experiences (% a) Bisoprolol fumarate Placebo (n = 132) % 5 to 20 mg (n = 273) % 2.5 to 40 mg (n = 404) % Skin increased sweating 1.5 0.7 1.0 Musculoskeletal arthralgia 2.3 2.2 2.7 Central Nervous System dizziness 3.8 2.9 3.5 headache 11.4 8.8 10.9 hypoaesthesia 0.8 1.1 1.5 Autonomic Nervous System dry mouth 1.5 0.7 1.3 Heart Rate/Rhythm bradycardia 0 0.4 0.5 Psychiatric vivid dreams 0 0 0 insomnia 2.3 1.5 2.5 depression 0.8 0 0.2 Gastrointestinal diarrhea 1.5 2.6 3.5 nausea 1.5 1.5 2.2 vomiting 0 1.1 1.5 Respiratory bronchospasm 0 0 0 cough 4.5 2.6 2.5 dyspnea 0.8 1.1 1.5 pharyngitis 2.3 2.2 2.2 rhinitis 3.0 2.9 4.0 sinusitis 1.5 2.2 2.2 URI 3.8 4.8 5.0 Body as a Whole asthenia 0 0.4 1.5 chest pain 0.8 1.1 1.5 fatigue 1.5 6.6 8.2 edema (peripheral) 3.8 3.7 3.0 a percentage of patients with event The following is a comprehensive list of adverse experiences reported with bisoprolol fumarate in worldwide studies, or in postmarketing experience (in italics): Central Nervous System Dizziness, unsteadiness, vertigo, syncope, headache, paresthesia, hypoesthesia, hyperesthesia, somnolence, sleep disturbances, anxiety/restlessness, decreased concentration/memory Autonomic Nervous System Dry mouth Cardiovascular Bradycardia, palpitations and other rhythm disturbances, cold extremities, claudication, hypotension, orthostatic hypotension, chest pain, congestive heart failure, dyspnea on exertion Psychiatric Vivid dreams, insomnia, depression.
Gastrointestinal Gastric/epigastric/abdominal pain, gastritis, dyspepsia, nausea, vomiting, diarrhea, constipation, peptic ulcer Musculoskeletal Muscle/joint pain, arthralgia, back/neck pain, muscle cramps, twitching/tremor. Skin Rash, acne, eczema, psoriasis, skin irritation, pruritus, flushing, sweating, alopecia, dermatitis, angioedema, exfoliative dermatitis, cutaneous vasculitis Special Senses Visual disturbances, ocular pain/pressure, abnormal lacrimation, tinnitus, decreased hearing, earache, taste abnormalities.
Metabolic Gout Respiratory Asthma/bronchospasm, bronchitis, coughing, dyspnea, pharyngitis, rhinitis, sinusitis, URI. Genitourinary Decreased libido/impotence, Peyronie’s disease, cystitis, renal colic, polyuria. Hematologic Purpura. General Fatigue, asthenia, chest pain, malaise, edema, weight gain, angioedema. In addition, a variety of adverse effects have been reported with other beta-adrenergic blocking agents and should be considered potential adverse effects of bisoprolol fumarate: Central Nervous System Reversible mental depression progressing to catatonia, hallucinations, an acute reversible syndrome characterized by disorientation to time and place, emotional lability, slightly clouded sensorium.
Allergic Fever, combined with aching and sore throat, laryngospasm, respiratory distress. Hematologic Agranulocytosis, thrombocytopenia, thrombocytopenic purpura. Gastrointestinal Mesenteric arterial thrombosis, ischemic colitis. Miscellaneous The oculomucocutaneous syndrome associated with the beta-blocker practolol has not been reported with bisoprolol fumarate during investigational use or extensive foreign marketing experience.
Laboratory Abnormalities In clinical trials, the most frequently reported laboratory change was an increase in serum triglycerides, but this was not a consistent finding. Sporadic liver test abnormalities have been reported. In the U.S. controlled trials experience with bisoprolol fumarate treatment for 4-12 weeks, the incidence of concomitant elevations in SGOT and SGPT from 1 to 2 times normal was 3.9%, compared to 2.5% for placebo.
No patient had concomitant elevations greater than twice normal. In the long-term, uncontrolled experience with bisoprolol fumarate treatment for 6-18 months, the incidence of one or more concomitant elevations in SGOT and SGPT from 1 to 2 times normal was 6.2%. The incidence of multiple occurrences was 1.9%. For concomitant elevations in SGOT and SGPT of greater than twice normal, the incidence was 1.5%.
The incidence of multiple occurrences was 0.3%. In many cases these elevations were attributed to underlying disorders, or resolved during continued treatment with bisoprolol fumarate. Other laboratory changes included small increases in uric acid, creatinine, BUN, serum potassium, glucose, and phosphorus and decreases in WBC and platelets.
These were generally not of clinical importance and rarely resulted in discontinuation of bisoprolol fumarate. As with other beta-blockers, ANA conversions have also been reported on bisoprolol fumarate. About 15% of patients in long-term studies converted to a positive titer, although about one-third of these patients subsequently reconverted to a negative titer while on continued therapy.
Adverse reaction frequency tables (US label) US FDA label
| Body System/Adverse Experience | All Adverse Experiences (% a) Bisoprolol fumarate | ||
| Placebo (n = 132) % | 5 to 20 mg (n = 273) % | 2.5 to 40 mg (n = 404) % | |
| Skin | |||
| increased sweating | 1.5 | 0.7 | 1.0 |
| Musculoskeletal | |||
| arthralgia | 2.3 | 2.2 | 2.7 |
| Central Nervous System | |||
| dizziness | 3.8 | 2.9 | 3.5 |
| headache | 11.4 | 8.8 | 10.9 |
| hypoaesthesia | 0.8 | 1.1 | 1.5 |
| Autonomic Nervous System | |||
| dry mouth | 1.5 | 0.7 | 1.3 |
| Heart Rate/Rhythm | |||
| bradycardia | 0 | 0.4 | 0.5 |
| Psychiatric | |||
| vivid dreams | 0 | 0 | 0 |
| insomnia | 2.3 | 1.5 | 2.5 |
| depression | 0.8 | 0 | 0.2 |
| Gastrointestinal | |||
| diarrhea | 1.5 | 2.6 | 3.5 |
| nausea | 1.5 | 1.5 | 2.2 |
| vomiting | 0 | 1.1 | 1.5 |
| Respiratory | |||
| bronchospasm | 0 | 0 | 0 |
| cough | 4.5 | 2.6 | 2.5 |
| dyspnea | 0.8 | 1.1 | 1.5 |
| pharyngitis | 2.3 | 2.2 | 2.2 |
| rhinitis | 3.0 | 2.9 | 4.0 |
| sinusitis | 1.5 | 2.2 | 2.2 |
| URI | 3.8 | 4.8 | 5.0 |
| Body as a Whole | |||
| asthenia | 0 | 0.4 | 1.5 |
| chest pain | 0.8 | 1.1 | 1.5 |
| fatigue | 1.5 | 6.6 | 8.2 |
| edema (peripheral) | 3.8 | 3.7 | 3.0 |
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy In rats, bisoprolol fumarate was not teratogenic at doses up to 150 mg/kg/day which is 375 and 77 times the MRHD on the basis of body weight and body surface area, respectively. Bisoprolol fumarate was fetotoxic (increased late resorptions) at 50 mg/kg/day and maternotoxic (decreased food intake and body weight gain) at 150 mg/kg/day.
The fetotoxicity in rats occurred at 125 times the MRHD on a body weight basis and 26 times the MRHD on the basis of body surface area. The maternotoxicity occurred at 375 times the MRHD on a body weight basis and 77 times the MRHD on the basis of body surface area. In rabbits, bisoprolol fumarate was not teratogenic at doses up to 12.5 mg/kg/day, which is 31 and 12 times the MRHD based on body weight and body surface area, respectively, but was embryolethal (increased early resorptions) at 12.5 mg/kg/day.
There are no adequate and well-controlled studies in pregnant women. Bisoprolol fumarate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers Small amounts of bisoprolol fumarate (< 2% of the dose) have been detected in the milk of lactating rats. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk caution should be exercised when bisoprolol fumarate is administered to nursing women.
Pharmacokinetics
The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population.
Less than 2% of the dose is excreted in the feces.
In subjects with creatinine clearance less than 40 mL/min, the plasma half-life is increased approximately threefold compared to healthy subjects.
In patients with cirrhosis of the liver, the elimination of bisoprolol fumarate is more variable in rate and significantly slower than that in healthy subjects, with plasma half-life ranging from 8.3 to 21.7 hours.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Bisoprolol fumarate is a beta 1 -selective (cardioselective) adrenoceptor blocking agent without significant membrane stabilizing activity or intrinsic sympathomimetic activity in its therapeutic dosage range. Cardioselectivity is not absolute, however, and at higher doses (≥ 20 mg) bisoprolol fumarate also inhibits beta 2 -adrenoceptors, chiefly located in the bronchial and vascular musculature; to retain selectivity it is therefore important to use the lowest effective dose.
Pharmacokinetics and Metabolism The absolute bioavailability after a 10 mg oral dose of bisoprolol fumarate is about 80%. Absorption is not affected by the presence of food. The first pass metabolism of bisoprolol fumarate is about 20%. Binding to serum proteins is approximately 30%. Peak plasma concentrations occur within 2-4 hours of dosing with 5 to 20 mg, and mean peak values range from 16 ng/mL at 5 mg to 70 ng/mL at 20 mg.
Once daily dosing with bisoprolol fumarate results in less than twofold intersubject variation in peak plasma levels. The plasma elimination half-life is 9-12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population. Steady state is attained within 5 days of once daily dosing.
In both young and elderly populations, plasma accumulation is low; the accumulation factor ranges from 1.1 to 1.3, and is what would be expected from the first order kinetics and once daily dosing. Plasma concentrations are proportional to the administered dose in the range of 5 to 20 mg. Pharmacokinetic characteristics of the two enantiomers are similar.
Bisoprolol fumarate is eliminated equally by renal and non-renal pathways with about 50% of the dose appearing unchanged in the urine and the remainder appearing in the form of inactive metabolites. In humans, the known metabolites are labile or have no known pharmacologic activity. Less than 2% of the dose is excreted in the feces.
Bisoprolol fumarate is not metabolized by cytochrome P450 II D6 (debrisoquin hydroxylase). In subjects with creatinine clearance less than 40 mL/min, the plasma half-life is increased approximately threefold compared to healthy subjects. In patients with cirrhosis of the liver, the elimination of bisoprolol fumarate is more variable in rate and significantly slower than that in healthy subjects, with plasma half-life ranging from 8.3 to 21.7 hours.
Pharmacodynamics The most prominent effect of bisoprolol fumarate is the negative chronotropic effect, resulting in a reduction in resting and exercise heart rate. There is a fall in resting and exercise cardiac output with little observed change in stroke volume, and only a small increase in right atrial pressure, or pulmonary capillary wedge pressure at rest or during exercise.
Findings in short-term clinical hemodynamics studies with bisoprolol fumarate are similar to those observed with other beta-blocking agents. The mechanism of action of its antihypertensive effects has not been completely established. Factors which may be involved include: 1. Decreased cardiac output, 2. Inhibition of renin release by the kidneys, 3.
Diminution of tonic sympathetic outflow from the vasomotor centers in the brain. In normal volunteers, bisoprolol fumarate therapy resulted in a reduction of exercise- and isoproterenol-induced tachycardia. The maximal effect occurred within 1-4 hours post-dosing. Effects persisted for 24 hours at doses equal to or greater than 5 mg.
Electrophysiology studies in man have demonstrated that bisoprolol fumarate significantly decreases heart rate, increases sinus node recovery time, prolongs AV node refractory periods, and, with rapid atrial stimulation, prolongs AV nodal conduction. Beta 1 -selectivity of bisoprolol fumarate has been demonstrated in both animal and human studies.
No effects at therapeutic doses on beta 2 -adrenoceptor density have been observed. Pulmonary function studies have been conducted in healthy volunteers, asthmatics, and patients with chronic obstructive pulmonary disease (COPD). Doses of bisoprolol fumarate ranged from 5 to 60 mg, atenolol from 50 to 200 mg, metoprolol from 100 to 200 mg, and propranolol from 40 to 80 mg.
In some studies, slight, asymptomatic increases in airways resistance (AWR) and decreases in forced expiratory volume (FEV 1) were observed with doses of bisoprolol fumarate 20 mg and higher, similar to the small increases in AWR also noted with the other cardioselective beta-blockers. The changes induced by beta-blockade with all agents were reversed by bronchodilator therapy.
Bisoprolol fumarate had minimal effect on serum lipids during antihypertensive studies. In U.S. placebo-controlled trials, changes in total cholesterol averaged +0.8% for bisoprolol fumarate-treated patients, and +0.7% for placebo. Changes in triglycerides averaged +19% for bisoprolol fumarate-treated patients, and +17% for placebo.
Bisoprolol fumarate has also been given concomitantly with thiazide diuretics. Even very low doses of hydrochlorothiazide (6.25 mg) were found to be additive with bisoprolol fumarate in lowering blood pressure in patients with mild-to-moderate hypertension.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Bisoprolol 5 mg Tablet | ₱1.25–₱15.67Reference ₱13.50 | per tablet | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Bisoprolol |
| PNF listing | Oral: 2.5 mg and 5 mg tablet (as fumarate) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. BISOPROLOL FUMARATE · Sun Pharmaceutical Industries, Inc. [US FDA-approved label, version 4, October 15, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7556f457-c4d3-49d6-b383-0ade6d489091
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .

